Compare LGIH & DRTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LGIH | DRTS |
|---|---|---|
| Founded | 2003 | 2015 |
| Country | United States | Israel |
| Employees | N/A | 121 |
| Industry | Homebuilding | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 978.2M |
| IPO Year | 2013 | N/A |
| Metric | LGIH | DRTS |
|---|---|---|
| Price | $64.06 | $10.94 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 3 |
| Target Price | ★ $75.90 | $8.67 |
| AVG Volume (30 Days) | 379.1K | ★ 909.6K |
| Earning Date | 04-28-2026 | 05-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.09 | N/A |
| Revenue | ★ $1,705,504,000.00 | N/A |
| Revenue This Year | $2.32 | N/A |
| Revenue Next Year | $17.94 | $699.98 |
| P/E Ratio | $682.67 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $33.55 | $2.87 |
| 52 Week High | $69.42 | $11.62 |
| Indicator | LGIH | DRTS |
|---|---|---|
| Relative Strength Index (RSI) | 73.43 | 61.42 |
| Support Level | $41.87 | $6.47 |
| Resistance Level | N/A | $11.48 |
| Average True Range (ATR) | 3.06 | 0.65 |
| MACD | 0.86 | 0.05 |
| Stochastic Oscillator | 96.92 | 95.96 |
LGI Homes Inc is engaged in the design, construction, and sale of new homes in markets. The company's current product offerings include entry-level homes, including both detached homes and townhomes, and move-up homes sold, which are sold under the LGI Homes brand, and luxury series homes, which are sold under the Terrata Homes brand. It offers a set number of floor plans in each community with features that include upgrades, such as granite countertops, appliances, and ceramic tile flooring. The company has seven operating segments: West, Northwest, Central, Midwest, Florida, Southeast, and Mid-Atlantic. The majority of the revenue is generated from the Central division segment.
Alpha Tau Medical Ltd is a clinical-stage oncology therapeutics company focused on harnessing the innate relative biological effectiveness and short range of alpha particles for use as a localized radiation therapy for solid tumors. Its proprietary Alpha DaRT technology is designed to utilize the specific therapeutic properties of alpha particles while aiming to overcome, and even harness for potential benefit, the traditional shortcomings of alpha radiation's limited range. The company has active clinical programs targeting a range of different tumor types, such as head and neck cancer, pancreatic cancer, brain cancer, liver metastases, lung cancer, and prostate cancer. Geographically, it operates in Israel, United States, and Japan with the majority of the revenue generated from Israel.